Masthercell adds to global gene and cell manufacturing frenzy Tuesday, March 26, 2019 Belgium-based Masthercell Global says it will build out a commercial-scale cell and gene manufacturing facility in its home country.
Bluebird gene therapy manufacturing facility up and running by Eric Palmer Tuesday, March 26, 2019 Bluebird Bio has completed a new lentiviral vector manufacturing facility to produce the investigational gene and cell therapies it is working on.
Senate bill proposes 'annuity' payments for pricey treatments by Arlene Weintraub Thursday, January 31, 2019 Two senators have introduced a bill designed to encourage deals that would allow insurers to spread payments for expensive therapies over time.
Alternative payment models to ‘reset the paradigm’: Novartis by Arlene Weintraub Tuesday, January 29, 2019 Novartis figures biopharma companies both large and small will need to embrace alternative payment models for pricey gene and cell therapies.
Maria Fardis—Iovance Biotherapeutics by Arlene Weintraub Maria Fardis, President and Chief Executive Officer, Iovance Biotherapeutics
Novartis looks ahead to China with Kymriah manufacturing pact by Eric Palmer Friday, September 28, 2018 Novartis is looking ahead to China for introduction of its CAR-T treatment Kymriah with a deal for manufacturing there.
Gilead’s Kite taps Eisai vet to helm CAR-T commercial strategy by Arlene Weintraub Tuesday, July 10, 2018 Eisai and Celgene veteran Michael Amoroso will take on the challenge of making Gilead's entrance into CAR-T cancer treatments a success.
Lonza moves cell work, cuts jobs at plant hit by warning letter by Eric Palmer Monday, March 5, 2018 The decision by Lonza to move cell-therapy work out of a U.S. facility that was hit by an FDA warning letter will cost the plant about 125 jobs.
FiercePharmaAsia—Astellas, Celltrion, Korea's digital health plan by Angus Liu Friday, February 16, 2018 Astellas buys Universal Cells, Teva is affected by Celltrion's manufacturing problem, Korea rolls out a digital health initiative.
Biotech vets weigh in on getting drugs through Gottlieb’s FDA by Arlene Weintraub Wednesday, September 27, 2017 New FDA commissioner Scott Gottlieb will build on progress the FDA was making in facilitating faster drug approvals, three biotech execs predicted.
